Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)

This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study d…

Invasive Breast CancerTriple Negative Breast CancerER-Negative Breast Cancer+2 more

Massachusetts General HospitalNCT04230109